Focus Partners Wealth
MYGN icon

Focus Partners Wealth’s Myriad Genetics MYGN Stock Holding History

Focus Partners Wealth’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$125K Buy
+21,857
New +$99.2K ﹤0.01% 2586
2026
Q1 		– Sell
-16,729
Closed -$103K – 2766
2025
Q4 		$103K Buy
+16,729
New +$121K ﹤0.01% 2546

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Focus Partners Wealth's MYGN Position: Q2 2026 in Review

Focus Partners Wealth opened a new position in Myriad Genetics (MYGN) in Q2 2026: 21,857 shares worth $125K. The stake represents ﹤0.01% of the portfolio and ranks #2586 among its holdings. This is a return to the name: Focus Partners Wealth previously reported a position in MYGN as recently as Q4 2025.

Focus Partners Wealth first reported a position in MYGN in Q4 2025 and has held it in 2 quarters since. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Focus Partners Wealth held 21,857 shares of Myriad Genetics worth $125K as of Q2 2026.
  • Myriad Genetics was a new Focus Partners Wealth position in Q2 2026.
  • Myriad Genetics made up ﹤0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #2586 holding.
  • Focus Partners Wealth first reported a position in Myriad Genetics in Q4 2025 and has held it in 2 quarters since.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.